P. Herzig

发表

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade

C. Klein, T. Schumacher, K. Mertz, 2018, Nature Medicine.

PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade

D. Lardinois, P. Herzig, Marcel P. Trefny, 2020, Cancer Immunology, Immunotherapy.

Humanized Monoclonal Antibody Blocking Carbonic Anhydrase 12 Enzymatic Activity Leads to Reduced Tumor Growth In Vitro

F. Stenner, P. Herzig, A. Zippelius, 2019, AntiCancer Research.

Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer

C. Klein, K. Mertz, R. Rosenberg, 2020, Journal for ImmunoTherapy of Cancer.

Esterase activity of carbonic anhydrases serves as surrogate for selecting antibodies blocking hydratase activity

P. Herzig, A. Zippelius, R. Zeidler, 2015, Journal of enzyme inhibition and medicinal chemistry.

A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer

K. Mertz, Z. Trajanoski, Dietmar Rieder, 2019, Clinical Cancer Research.

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors

C. Klein, D. Marbach, K. Mertz, 2022, Journal for immunotherapy of cancer.

An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer

A. Broeks, T. Schumacher, C. Blank, 2021, Nature Medicine.

Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor

C. Klein, M. Bacac, P. Pisa, 2016, Oncoimmunology.

Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy

A. Zingg, C. Hess, Jérémie Rossy, 2023, Nature Communications.

Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment

P. Herzig, A. Zippelius, J. Schreiner, 2015, Cancer Immunology Research.

Induced PD-L 1 Expression Mediates Acquired Resistance to Agonistic Anti-CD 40 Treatment

P. Herzig, A. Zippelius, J. Schreiner, 2015 .

The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors

K. Mertz, D. Lardinois, V. Koelzer, 2018, Oncoimmunology.

Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

Jens Schreiner, Anton Belousov, Didier Lardinois, 2015, Cancer Immunology Research.

Integrated functional and spatial profiling of tumour immune responses induced by immunotherapy: the iPROFILER platform

I. Zlobec, D. Lardinois, D. Thommen, 2021, Immuno-oncology technology.

Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma

P. Herzig, H. Läubli, Beckey Trinh, 2019, Journal of Immunotherapy for Cancer.

Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity

P. Herzig, A. Zippelius, R. Mohanlal, 2021, Frontiers in Oncology.

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade

C. Klein, T. Schumacher, K. Mertz, 2018, Nature Network Boston.

Changes of peripheral T cell subsets in melanoma patients with immune-related adverse events

P. Herzig, A. Zippelius, H. Läubli, 2023, Frontiers in Immunology.

Engagement of sialylated glycans with Siglec receptors on myeloid suppressor cells inhibit anti-cancer immunity via CCL2

A. Zingg, D. Lardinois, P. Herzig, 2023, bioRxiv.

Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

C. Klein, M. Bacac, P. Pisa, 2015, Cancer Immunology Research.

Multimodal single-cell profiling of T cell specificity and reactivity in lung cancer

S. Reddy, P. Herzig, Marcel P. Trefny, 2023, bioRxiv.

Protocol for ex vivo culture of patient-derived tumor fragments

D. Thommen, P. Herzig, A. Zippelius, 2023, STAR protocols.

Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2.

P. Herzig, H. Läubli, Ronja Wieboldt, 2024, Cellular & molecular immunology.

66P Highly exhausted PD-1hi T cell subsets in human NSCLC are co-defined by the predominant expression of distinct inhibitory receptors and correlate with clinical outcome.

D. Thommen, P. Herzig, A. Zippelius, 2016, Journal of Thoracic Oncology.